title: Glesatinib
text: # Glesatinib
  
  Glesatinib (MGCD265) is an experimental anti-cancer drug.
  
  It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).
  
  It is a spectrum selective tyrosine kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".
  
  